Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of BIND Therapeutics (NASDAQ: BIND ) , a clinical-stage nanomedicine platform company, fell as much as 11% after announcing the departure of its chief medical officer, Greg Berk.
So what: According to BIND's press release, which came immediately after the closing bell yesterday, Berk will be leaving to "pursue another opportunity," but will continue serving as an adviser to the company until his departure. BIND notes that Edward Schnipper, who has previously served as an advisor for the company and its chief medical officer, will fill the position on an interim basis.
Now what: We don't have to read too far into investors' fears today. The loss of CMO Greg Berk in the middle of enrollments for its mid-stage study of its most advanced drug candidate, BIND-014, for the treatment of non-small-cell lung cancer and prostate cancer, has investors concerned that the company might somehow lose focus. I, personally, wouldn't be too concerned with today's untimely departure and would instead let the phase 2 data from these upcoming trials do the talking later this year.
Here's a stock you should really have your eyes on in 2014
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.